What is it about?
Zidovudine (old anti-HIV drug), has unexploited antibacterial properties and has been considered for drug repurposing. We tested 36 MDR Enterobacterales for the combination zidovudine + fosfomycin. A synergistic effect was observed in 25 isolates and no antagonistic effect was observed. For 7 of 8 fosfomycin-resistant strains, zidovudine combination was able to restore fosfomycin susceptibility. Synergistic activity was observed for fosfomycin + zidovudine in 69.4% of the tested strains in the animal model.
Featured Image
Photo by CDC on Unsplash
Why is it important?
It highlights the antibacterial potential of zidovudine
Perspectives
Studies on zidovudine against MDR bacteria are welcomed
Professor Stefano Di Bella
Universita degli Studi di Trieste
Read the Original
This page is a summary of: Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales, International Journal of Antimicrobial Agents, July 2021, Elsevier,
DOI: 10.1016/j.ijantimicag.2021.106362.
You can read the full text:
Contributors
The following have contributed to this page
